in Cancer Research

Dr. Clay Siegall Is Achieving Great Things Through Seattle Genetics

Dr. Clay Siegall is the co-founder of the ever growing cancer research and development facility Seattle Genetics. The company was established in 1998. He serves as the Chairman of the Board, President, and CEO. He created Seattle Genetics with the hopes of developing new cancer drugs that would help treat patients that were not responding well to other forms of treatment. Dr. Clay Siegall is a scientist that has worked with some of the most notable cancer research and development companies. Adcetris is the companies most widely used creation and is an antibody-drug conjugate. It was approved for use by the FDA in 2011. The Takeda Pharmaceutical Company was key in helping to create this now globally available cancer treatment drug.

Dr. Clay Siegall has managed to provide superior leadership which has enable the company to obtain several licenses for ADC technology with many pharmaceutical giants.These licenses have helped the company generate over $350 million. Seattle Genetics currently has over 20 ADCs in the final phase of testing and will be available for use in the near future. In total, Seattle Genetics has raised over $1.2 billion in funding through their fundraising efforts. This includes both public and private funds.

Before co-founding Seattle Genetics, Dr. Clay Siegall worked for the National Cancer Institute, Bristol-Myers Squibb, and the Pharmaceutical Research Institue. He developed his scientific knowledge of cancer treatments and research techniques while working at these major companies. He knew that he wanted to make a difference through cancer treatment development which spurred him to create Seattle Genetic. Serving in an executive capacity for the facility has helped them achieve a great deal of success since they began in 1998. They are working hard to create new treatments that will help people that suffer from specific types of cancer that might not respond well the available treatments that are currently on the market. He has also served in an executive capacity for many other facilities in addition to winning many prestigious awards. He also is an accomplished author having written over seventy publications. He also holds fifteen patents. He attended the University of Maryland where he attained his B.S. in Zoology. He later went on the receive a Ph.D. from George Washington University in Genetics.

Write a Comment